Study Title
MIRASOL: A randomized, open label, phase 3 study of Mirvetuximab Soravtansine vs. Investigator’s choice of chemotherapy in Platinum-Resistant Advance High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with high folate receptor-alpha expression. (GOG 3045)
Purpose
To compare the progression-free survival of patients randomized to Mirvetuximab Soravtansine vs. investigator’s choice of chemotherapy.
Eligibility
Study Process
Trial Details
Investigator:
Destin Black, M.D.
IRB:
Western
IRB Number:
Trial Type:
NA
Sponsor:
Immunogen
Contact Information:
Gynecologic Oncology Associates
(318) 212-8727
http://www.wkgynonc.com